Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of SPRO revenue | Skew |
|---|---|---|---|
| GSKGSK | <0.01% | 1.00% | 658× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In addition to the milestones described above, GSK is obligated to pay royalties to us on annual net sales of GSK Licensed Products in the GSK Territory. Such royalties are 1% for annual sales up to $750.0 million each year and range from high single-digit percentages on annual net sales above $750.0 million each year to low double-digit percentages on annual net sales above $1,000.0 million each year.”
$668,020 relationship658× more of SPRO’s book than GSK’s
basisSPRO fy2025 · closed 2025-12 $67MGSK fy2025 · closed 2025-12 $43.9B
FILING10-K0001193125-26-126192cik 0001701108
“The Meiji License requires us to pay future milestone payments of up to $1.0 million upon the achievement of specified regulatory milestones and royalties of 1% of net sales on a product-by-product and country-by-country basis.”
FILING10-K0001193125-26-126192cik 0001701108
“During the year ended December 31, 2025 we recognized $12.6 million in collaboration revenue related to our agreement with Pfizer, all of which was recognized upon termination of our agreement with Pfizer in December 2025.”
FILING10-K0001193125-26-126192cik 0001701108
“We recognize funding received from BARDA and the NIAID of the NIH, as revenue, rather than as a reduction of research and development expenses, because we are the principal in conducting the research and development activities and these contracts are central to our ongoing operations.”
FILING10-K0001193125-26-126192cik 0001701108
“Under the terms of the termination agreement, (i) in the event that a product is ever commercialized in the Pfizer Territory by Spero or any successor-in-interest to SPR206, such party will pay Pfizer royalties on the net sales in the Pfizer Territory at the rates set forth in the Pfizer License Agreement and (ii) we are liable to Pfizer for up to $5 million from any future sale, divestiture, license, transfer or partnering of SPR206.”
FILING10-K0001193125-26-126192cik 0001701108
“Under an agreement we entered into with PBB, Cantab Anti-Infectives Ltd. and New Pharma License Holdings Limited, we are obligated to make milestone payments of up to $5.8 million upon the achievement of specified clinical milestones and a payment of £5.0 million ($6.7 million as of December 31, 2025) upon the achievement of a specified commercial milestone for SPR206.”
FILING10-K0001193125-26-126192cik 0001701108
“Under the Sales Agreement, Cantor may sell shares of our common stock by any method permitted by law deemed to be an "at-the-market" offering as defined in Rule 415 of the Securities Act, subject to the terms of the Sales Agreement.”
FILING10-K0001193125-26-126192cik 0001701108
“Under an agreement we entered into with PBB, Cantab Anti-Infectives Ltd. and New Pharma License Holdings Limited, we are obligated to make milestone payments of up to $5.8 million upon the achievement of specified clinical milestones and a payment of £5.0 million ($6.7 million as of December 31, 2025) upon the achievement of a specified commercial milestone for SPR206.”
FILING10-K0001193125-26-126192cik 0001701108
“In addition, we have agreed to pay PBB royalties, on a product-by-product and country-by-country basis, of a low single-digit percentage based on net sales of products licensed under the agreement.”
FILING10-K0001193125-26-126192cik 0001701108
Watchlist prices, news filtered to it, and its next report on your desk.
Spero Therapeutics, Inc. has 6 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Spero Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
SPRO (Spero Therapeutics, Inc.) has 6 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PFE −0.67%, in healthcare.
Prev close 1.12 · gapped above the open, then crossed back over prior close. High/low 1.15 at 9:30 am ET, 1.12 at 3:30 pm ET.
Spero Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations